CRB1 and neovascular glaucoma: We suggest close follow up for all LCA patients who have CRB1 mutations, especially the c.2555T >C (p.I852T) homozygote variant searching for any vascular abnormality and managing it as soon as it is diagnosed with PPV and endolaser in an attempt to halt the complete loss of the already severely affected visual function, preserve the eye and prevent neovascular glaucoma and painful blind eye.